HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and maintained a price target of $24.
July 21, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $24.
The reiteration of a 'Buy' rating and a maintained price target of $24 by HC Wainwright & Co. indicates a positive outlook for Catalyst Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100